Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease

Bibliography

• Lee JC, Young PR. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 1996;59(2):152–7
   PubMed Web of Science ®Google Scholar
• Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739–46
   PubMed Web of Science ®Google Scholar
• Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997;272(38):23668–74
   PubMed Web of Science ®Google Scholar
• O’Callaghan C, Fanning LJ, Barry OP. p38δ MAPK: Emerging Roles of a Neglected Isoform. Int J Cell Biol 2014;2014:272689
   PubMedGoogle Scholar
• Meng F, Wu G. Is p38γ MAPK a metastasis-promoting gene or an oncogenic property-maintaining gene? Cell Cycle 2013;12(14):2329–30
   PubMed Web of Science ®Google Scholar
• Yang K, Liu Y, Liu Z, et al. p38γ overexpression in gliomas and its role in proliferation and apoptosis. Sci Rep 2013;3:2089
   Google Scholar
• Salituro FG, Germann UA, Wilson KP, et al. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999;6(9):807–23
   PubMed Web of Science ®Google Scholar
• Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185–201
   PubMed Web of Science ®Google Scholar
• Fischer S, Koeberle SC, Laufer SA. p38alpha mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011). Expert Opin Ther Pat 2011;21:1843–66
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD 2014). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf
   Google Scholar
• Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4(7):526–34
   PubMedGoogle Scholar
• Norman P. New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule. Expert Opin Investig Drugs 2013;22(12):1569–80
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80(2):89–95
   PubMed Web of Science ®Google Scholar
• Beghè B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 2013;188(3):271–8
   PubMed Web of Science ®Google Scholar
• Antoniu SA. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011;6:147–55
   PubMed Web of Science ®Google Scholar
• Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med 2012;106(3):319–28
   PubMed Web of Science ®Google Scholar
• Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31(1):62–9
   PubMed Web of Science ®Google Scholar
• Gaffey K, Reynolds S, Plumb J, et al. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J 2013;42(1):28–41
   PubMed Web of Science ®Google Scholar
• Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011;338(3):732–40
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131(3):636–45
   PubMed Web of Science ®Google Scholar
• Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67(7):909–16
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60(2):335–44
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011;38(5):846–54
   PubMed Web of Science ®Google Scholar
• Genovese MC. Inhibition of p38: has the Fat Lady Sung? Arthritis Rheum 2009;60(2):317–20
   PubMed Web of Science ®Google Scholar
• Clark AR, Dean JL. The p38 MAPK Pathway in Rheumatoid Arthritis: a Sideways Look. Open Rheumatol J 2012;6:209–19
   PubMedGoogle Scholar
• Malemud CJ. Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Antiinflamm Antiallergy Agents Med Chem 2011;10(2):78–84
   PubMedGoogle Scholar
• Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013;13(9):679–92
   PubMed Web of Science ®Google Scholar
• Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011;51(4):485–90
   PubMed Web of Science ®Google Scholar
• Lin X, Wang M, Zhang J, Xu R. p38 MAPK: potential target of chronic pain. Curr Med Chem 2014;21(38):4405–18
   PubMed Web of Science ®Google Scholar
• Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 2009;18(12):1893–905
   PubMed Web of Science ®Google Scholar
• Chiesi Farmaceutici S.P.A. Kinase Inhibitors. WO2013083606; 2013
   Google Scholar
• Safety & Efficacy of BCT197A2201 in chronic obstructive pulmonary disease (copd) patients presenting with an exacerbation. Available from: https://clinicaltrials.gov/ct2/show/NCT01332097
   Google Scholar
• Novartis AG. 5-membered heterocycle-based p38 kinase inhibitors. US 8242117; 2012
   Google Scholar
• Novartis AG. Use of a Pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease. WO2013139809; 2013
   Google Scholar
• Aston NM, Bamborough P, Buckton JB, et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem 2009;52(20):6257–69
   PubMed Web of Science ®Google Scholar
• Watz H, Barnacle H, Hartley B, Chan RA. Randomised, double-blind, placebo-controlled trial of the efficacy and safety of losmapimod in patients with chronic obstructive pulmonary disease. Lancet Respir Med 2014;2(1):63–72
   PubMed Web of Science ®Google Scholar
• Fisk M, Mohan D, Cheriyan J, et al. Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (‘EVOLUTION’): rationale and protocol. Artery Res 2014;8(1):24–34
   Google Scholar
• Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012;52(3):416–24
   PubMed Web of Science ®Google Scholar
• Xing L, Devadas B, Devraj RV, et al. Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate. ChemMedChem 2012;7(2):273–80
   PubMed Web of Science ®Google Scholar
• Hope HR, Anderson GD, Burnette BL, et al. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 2009;331(3):882–95
   PubMed Web of Science ®Google Scholar
• MacNee W, Allan RJ, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013;68(8):738–45
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of PH-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) taking salmeterol xinafoate/fluticasone propionate combination. Available from: https://clinicaltrials.gov/ct2/show/NCT01321463
   Google Scholar
• Fogel R, Shields K, Christensen J, et al. A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA [abstract 186]. Annual Congress of the European Respiratory Society, Barcelona; 7-11 September 2013; 2013
   Google Scholar
• Study to evaluate the efficacy and safety of ph-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (copd) on a background of tiotropium bromide. Available from: https://clinicaltrials.gov/ct2/show/NCT01543919
   Google Scholar
• Tan E, Jones I, Tweedy S, et al. The novel oral p38 inhibitor, PH-797804, inhibits inhaled lipopolysaccharide (lps)-induced airway and systemic inflammatory markers. In healthy subjects ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A2554
   Google Scholar
• Single dose lipopolysaccharide (lps) study in healthy volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT01314885
   Google Scholar
• Singh D, Smyth L, Borrill Z, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010;50(1):94–100
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Betts JC, Warnock LC, et al. Differential regulation of camp receptor protein (CRP) and fibrinogen gene expression by the p38 mitogen-activated protein (MAP) kinase inhibitor dilmapimod in blood samples obtained in a randomised, placebo controlled study in chronic obstructive pulmonary disease (COPD). Available from: www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A4954
   Google Scholar
• Barnes N, Pavord I, Maden C, et al. Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD. Eur Respir J 2009;34(Suppl 53):648s
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient. WO-2010071583; 2010
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Ltd. Pyrazinone derivatives and their use in the treatment of lung diseases. WO-2009001132; 2009
   Google Scholar
• To assess the safety, tolerability, and pharmacokinetics of azd7624 in healthy volunteers and copd patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01817855
   Google Scholar
• A phase iia study to investigate the efficacy and safety of azd7624 in chronic obstructive pulmonary disease (COPD) patients while on maintenance therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT02238483
   Google Scholar
• Millan DS, Bunnage ME, Burrows JL, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54(22):7797–814
   PubMed Web of Science ®Google Scholar
• Kilty I, Clarke N, Fairmain D, et al. PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease P1764. Available from: www.ersnet.org/learning_resources_player/abstract_print_13/files/196.pdf
   Google Scholar
• Russell V, Foster M, Spicer D, et al. The effects of pf03715455 and roflumilast on cellular and tissue inflammation [abstract A1504]. In an 11 day tobacco-smoke exposed mouse model Of COPD, abstracts of the American Thoracic Society, Philadelphia; 17-22 May 2013
   Google Scholar
• An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma. Available from: https://clinicaltrials.gov/ct2/show/NCT02219048
   Google Scholar
• Johnson & Johnson, Centocor Ortho Biotech Inc. acquires respivert ltd., strengthens pulmonary focus acquisition bolsters pulmonary portfolio and capabilities, accessing promising pipeline of first-in-class compounds and renowned team of respiratory scientists, Press release, 1 June 2010
   Google Scholar
• Charron C, Coates M, Ito K, et al. Superior effects Of RV568, a novel narrow spectrum kinase inhibitor, To BIRB796, A p38mapk inhibitor, on pro-inflammatory cytokine roduction. In macrophages, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A3088
   Google Scholar
• Contoli C, Ito K, Papi A. Effects of rv568, a narrow spectrum kinase inhibitor, on hrv16 replication and cytokine production. In Airway epithelial cells obtained from COPD patients ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A2766
   Google Scholar
• Knoblock J, Urban K, Jungck D, et al. Effects of rv568, a narrow spectrum kinase inhibitor, on pro-inflammatory cytokine production. In Smooth muscle cells obtained from COPD patients, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A3613
   Google Scholar
• Ito K, Vuppusetty C, To M, Rapeport G. Effects of rv568, a narrow spectrum kinase inhibitor. On human rhinovirus replication and cytokine production, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A2765
   Google Scholar
• Contoli M, Ito K, Poletti D, et al. Novel narrow spectrum kinase inhibitors inhibit rhinovirus replication via enhancement of interferon expression in nasal epithelial cells of atopic and non-atopic patients. Eur Respir J 2011;p3495
   Google Scholar
• Ito K, Vuppusetty C, To M. Effects of rv568, a narrow spectrum kinase inhibitor. On haemophillus influenzae infection to bronchial epithelial cells, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A3359
   Google Scholar
• Kizawa Y, Kimura G, Saito R, et al. Effects Of RV568, A narrow spectrum kinase inhibitor. on airway inflammation and hyperresponsiveness. In tobacco-smoke exposed mice, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A3103
   Google Scholar
• Langenbach S, Dousha L, Gulano RC, et al. Effects Of RV568, a narrow spectrum kinase inhibitor (NSKI), on influenza infection. In cigarette-smoke exposed mice, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A3366
   Google Scholar
• Charron C, Coates M, Ito K, et al. Superior effects of rv1088, a novel narrow spectrum kinase inhibitor, To BIRB796, A P38MAPK inhibitor, on pro-inflammatory cytokine production. In macrophages, ajrccm-conference, Denver; 13-18 May 2011;2011. 183.1_MeetingAbstracts.A4538
   Google Scholar
• Onions S. The discovery and profile of narrow spectrum kinase inhibitors as novel treatments for inflammatory pulmonary disease. 17th RSC/SCI medicinal chemistry symposium; Cambridge, 8-11 September 2013
   Google Scholar
• Respivert Ltd. p38 map kinase inhibitors. WO- 2010038085; 2010
   Google Scholar
• Respivert Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. WO2010112936; 2013
   Google Scholar
• RV568 - Viral Challenge With RSV. Available from: https://clinicaltrials.gov/ct2/show/NCT01230645
   Google Scholar
• Vienna Challenge Chamber Study Using RV568 in Subjects With Allergic Rhinitis. Available from: https://clinicaltrials.gov/ct2/show/NCT01230619
   Google Scholar
• Cass L, Woodward K, Brindley C, et al. Tolerability and pharmacokinetic profile Of RV568, a narrow spectrum kinase inhibitor, following single and repeat inhaled dosing. In healthy volunteers, 10.1164/ajrccm-conference, Philadelphia; 17-22 May 2013; 2013. 187.1_MeetingAbstracts.A4117
   Google Scholar
• Russell P, Cass L, Ito K, et al. Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients. Eur Resp J 2013;42:1371
   Google Scholar
• Ito K, Charron C, Cass L, et al. Pharmacodynamic analysis of rv568, a narrow spectrum kinase inhibitor, following single and repeat intranasal dosing. In healthy volunteers, 10.1164/ajrccm-conference, Philadelphia; 17-22 May 2013; 2013. 187.1_MeetingAbstracts.A1494
   Google Scholar
• An Effectiveness and safety study of inhaled jnj 49095397 (rv568) in patients with moderate to severe chronic obstructive pulmonary disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01867762
   Google Scholar
• Marumo S, Hoshino Y, Kiyokawa H, et al. p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice. BMC Pulm Med 2014;14:79
   PubMed Web of Science ®Google Scholar
• Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139(6):1470–9
   PubMed Web of Science ®Google Scholar